KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Abstract

KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).

Keywords

MeSH Terms

Affiliated Institutions

• Cleveland Clinic US
• Sarah Cannon US
• Centre Hospitalier Universitaire de Rennes FR
• University of Miami US
• University of Rochester Medical Center US
• Colorado Blood Cancer Institute US
• University of California, Los Angeles US
• Texas Oncology US
• Inserm FR
• Universitätsklinikum Würzburg DE
• Hackensack University Medical Center US
• Stanford University US
• Moffitt Cancer Center US
• Amsterdam UMC Location University of Amsterdam NL
• The Ohio State University US
• Dana-Farber Cancer Institute US
• Fox Chase Cancer Center US
• Tennessee Oncology US
• Cancer Institute (WIA) IN
• Gilead Sciences (France) FR
• The University of Texas MD Anderson Cancer Center US
• University of Amsterdam NL

Related Publications